Structural insight into the substrate specificity of phosphodiesterases

Handbook of Experimental Pharmacology

Volumn 204, Issue , 2011, Pages 121-134

  Ke, Hengming ^a   Wang, Huanchen ^a   Ye, Mengchun ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

cAMP; cGMP; Crystal structure; Substrate specificity

Indexed keywords

ADENOSINE PHOSPHATE; ASPARTIC ACID; CYCLIC AMP; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; GLUTAMINE; GLYCINE; GUANOSINE PHOSPHATE; HISTIDINE; PHENYLALANINE; PHOSPHODIESTERASE 10; PHOSPHODIESTERASE 10A; PHOSPHODIESTERASE 10A2; PHOSPHODIESTERASE 11; PHOSPHODIESTERASE 2A3; PHOSPHODIESTERASE 4D2; PHOSPHODIESTERASE 8; PHOSPHODIESTERASE 9A2; PHOSPHODIESTERASE I; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE V; PHOSPHODIESTERASE VI; PHOSPHODIESTERASE VII; SPLEEN EXONUCLEASE; TYROSINE; UNCLASSIFIED DRUG; PHOSPHODIESTERASE;

CARBOXY TERMINAL SEQUENCE; CATALYSIS; CRYSTAL STRUCTURE; ENZYME ACTIVE SITE; ENZYME SPECIFICITY; ENZYME STRUCTURE; ENZYME SUBSTRATE COMPLEX; HUMAN; HYDROLYSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEQUENCE ALIGNMENT; ANIMAL; BINDING SITE; CHEMISTRY; METABOLISM;

ANIMALS; BINDING SITES; CYCLIC AMP; CYCLIC GMP; HUMANS; PHOSPHORIC DIESTER HYDROLASES; SUBSTRATE SPECIFICITY;

EID: 79960895040     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-17969-3_4     Document Type: Review

References (40)

1. Antoni F (2000) Molecular diversity of cyclic AMP signaling. Front Neuroendocrinol 21:103-132 (Pubitemid 30228501)
2. Beavo JA, Hardman JG, Sutherland EW (1970) Hydrolysis of cyclic guanosine and adenosine 3′, 5′-monophosphates by rat and bovine tissues. J Biol Chem 245:5649-5655
3. Bender AT, Beavo JA (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58:488-520 (Pubitemid 44394910)
4. Bolger GB, Erdogan S, Jones RE, Loughney K, Scotland G, Hoffmann R, Wilkinson I, Farrell C, Houslay MD (1997) Characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene. Biochem J 328:539-548 (Pubitemid 27515598)
5. Burgin AB, Magnusson OT, Singh J, Witte P, Staker BL, Bjornsson JM, Thorsteinsdottir M, Hrafnsdottir S, Hagen T, Kiselyov AS, Stewart LJ, Gurney ME (2010) Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Nat Biotechnol 28:63-70
6. Butcher RW, Sutherland EW (1962) Adenosine 3′, 5′-phosphate in biological materials. I. purification and properties of cyclic 3′5′-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3′, 5′-phosphate in human urine. J Biol Chem 237:1244-1250
7. Butt E, Beltman J, Becker DE, Jensen GS, Rybalkin SD, Jastorff B, Beavo JA (1995a) Characterization of cyclic nucleotide phosphodiesterases with cyclic GMP analogs: topology of the catalytic domains. Mol Pharmacol 47:330-339
8. Butt E, Beltman J, Becker DE, Jensen GS, Rybalkin SD, Jastorff B, Beavo JA (1995b) Characterization of cyclic nucleotide phosphodiesterases with cyclic AMP analogs: topology of the catalytic sites and comparison with other cyclic AMP-binding proteins. Mol Pharmacol 47:340-347
9. Conti M, Beavo J (2007) Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 76:481-511
10. Fisher DA, Smith JF, Pillar JS, St Denis SH, Cheng JB (1998) Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J Biol Chem 273:15559-15564 (Pubitemid 28298168)
11. Francis SH, Zoraghi R, Kotera J, Ke H, Bessay EP, Blouni MA, Corbin JD (2006) Phoephodiesterase 5: Molecular characteristics relating to structure, function, and regulation. In: Beavo JA, Francis SH, Houslay MS (eds) Cyclic nucleotide phosphodiesterases in health and disease. CRC Press, Boca Raton, FL, pp 131-164
12. Hannila SS, Filbin MT (2008) The role of cyclic AMP signaling in promoting axonal regeneration after spinal cord injury. Exp Neurol 209:321-332 (Pubitemid 351174133)
13. Hitchcock M (1973) Adenosine 3′, 5′-cyclic monophosphate phosphodiesterase in guineq-pig lung-properties and effect of adrenergic drugs. Biochem Pharmacol 22:959-969
14. Horvath A, Stratakis CA (2008) Unraveling the molecular basis of micronodular adrenal hyperplasia. Curr Opin Endocrinol Diabetes Obes 15:227-233 (Pubitemid 351595186)
15. Houslay MD (1998) Adaptation in cyclic AMP signaling processes: a central role for cyclic AMP phosphodiesterases. Cell Develop Biol 9:161-167 (Pubitemid 128352267)
16. Huai Q, Colicelli J, Ke H (2003) The crystal structure of AMP-bound PDE4 suggests a mechanism for phosphodiesterase catalysis. Biochemistry 42:13220-13226 (Pubitemid 37420675)
17. Huai Q, Wang H, Zhang W, Colman R, Robinson H, Ke H (2004) Crystal structure of phosphodiesterase 9 shows orientation variation of inhibitor 3-isobutyl-1-methylxanthine binding. Proc Natl Acad Sci USA 101:9624-9629 (Pubitemid 38869286)
18. Iffland A, Kohls D, Low S, Luan J, Zhang Y, Kothe M, Cao Q, Kamath AV, Ding YH, Ellenberger T (2005) Structural determinants for inhibitor specificity and selectivity in PDE2A using the wheat germ in vitro translation system. Biochemistry 44:8312-8325 (Pubitemid 40799912)
19. Lee CH, Evans FE, Sarma RH (1975) Interaction between glycosidic torsion, sugar pucker, and backbone conformation in 50-b-nucleotides. J Biol Chem 250:1290-1296
20. Liu S, Mansour MN, Dillman KS, Perez JR, Danley DE, Aeed PA, Simons SP, Lemotte PK, Menniti FS (2008) Structural basis for the catalytic mechanism of human phosphodiesterase 9. Proc Natl Acad Sci USA 105:13309-13314
21. Lugnier C (2006) Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 109:366-398 (Pubitemid 43132818)
22. Mehats C, Andersen CB, Filopanti M, Jin SL, Conti M (2002) Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling. Trends Endocrinol Metab 13:29-35 (Pubitemid 36734013)
23. Monn E, Christiansen RO (1971) Adenosine 30, 50-monophosphate phosphodiesterase: multiple molecular forms. Science 173:540-542
24. Omori K, Kotera J (2007) Overview of PDEs and their regulation. Circ Res 100:309-327
25. ONeill JS, Maywood ES, Chesham JE, Takahashi JS, Hastings MH (2008) cAMP-dependent signaling as a core component of the mammalian circadian pacemaker. Science 320:949-953 (Pubitemid 351929593)
26. Piper M, van Horck F, Holt C (2007) The role of cyclic nucleotides in axon guidance. Adv Exp Med Biol 621:134-143
27. Scapin G, Patel SB, Chung C, Varnerin JP, Edmondson SD, Mastracchio A, Parmee ER, Singh SB, Becker JW, Van der Ploeg LH, Tota MR (2004) Crystal structure of human phosphodiesterase 3B: atomic basis for substrate and inhibitor specificity. Biochemistry 43:6091-6100 (Pubitemid 38669477)
28. Soderling SH, Bayuga SJ, Beavo JA (1998) Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases. J Biol Chem 273:15553-15558 (Pubitemid 28298167)
29. Turko IV, Francis SH, Corbin JD (1998) Hydropathic analysis and mutagenesis of the catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase (PDE5). cGMP versus cAMP substrate selectivity. Biochemistry 37:4200-4205 (Pubitemid 28166442)
30. Wang H, Liu Y, Chen Y, Robinson H, Ke H (2005) Multiple elements jointly determine inhibitor selectivity of cyclic nucleotide phosphodiesterases 4 and 7. J Biol Chem 280:30949-30955 (Pubitemid 41291827)
31. Wang H, Liu Y, Huai Q, Cai J, Zoraghi R, Francis SH, Corbin JD, Robinson H, Xin Z, Lin G, Ke H (2006) Multiple conformations of phosphodiesterase-5: implications for enzyme function and drug development. J Biol Chem 281:21469-21479 (Pubitemid 44115485)
32. Wang H, Liu Y, Hou J, Zheng M, Robinson H, Ke H (2007a) Structural insight into substrate specificity of phospodiesterase 10. Proc Natl Acad Sci USA 104:5782-5787 (Pubitemid 47175611)
33. Wang H, Robinson H, Ke H (2007b) The molecular basis for recognition of different substrates by phosphodiesterase families 4 and 10. J Mol Biol 371:302-307 (Pubitemid 47048279)
34. Wang H, Yan Z, Yang S, Cai J, Robinson H, Ke H (2008) Kinetic and structural studies of phosphodiesterase-8A and implication on the inhibitor selectivity. Biochemistry 47:12760-12768
35. Xu RX, Hassell AM, Vanderwall D, Lambert MH, Holmes WD, Luther MA, Rocque WJ, Milburn MV, Zhao Y, Ke H, Nolte RT (2000) Atomic structure of PDE4: Insight into phosphodiesteras mechanism and specificity. Science 288:1822-1825 (Pubitemid 30399019)
36. Yan Z, Wang H, Cai J, Ke H (2008) Refolding and kinetic characterization of the phosphodiesterase-8A catalytic domain. Protein Expr Purif 64:82-88
37. Yathindra N, Sunderalingam M (1974) Conformations of cyclic 3′, 5′-nucleotides. Effect of the base on the Syn-Anti conformer distribution. Biochem Biophys Res Commun 56:119-126
38. Zaccolo M, Movsesian MA (2007) cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology. Circ Res 100:1569-1578 (Pubitemid 46897260)
39. Zhang KY, Card GL, Suzuki Y, Artis DR, Fong D, Gillette S, Hsieh D, Neiman J, West BL, Zhang C, Milburn MV, Kim SH, Schlessinger J, Bollag G (2004) A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases. Mol Cell 15:279-286 (Pubitemid 38950974)
40. Zoraghi R, Corbin JD, Francis SH (2006) Phosphodiesterase-5 Gln817 is critical for cGMP, vardenafil, or sildenafil affinity; its orientation impacts cGMP but not cAMP affinity. J Biol Chem 281:5553-5558 (Pubitemid 43847651)